Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Technical Officer

President and CEO

CHIEF FINANCIAL OFFICER

EVP of R&D

SVP, General Counsel

GENERAL COUNSEL

SVP, Finance

VP, Corporate Counsel

Chief Financial Officer

General Counsel

EVP of R&D and CMO

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cel...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-22	Premium	sold (taxes)	Premium	Premium	Premium	Chief Technical Officer
2024-03-14	Premium	sold (taxes)	Premium	Premium	Premium	President and CEO
2024-01-30	Premium	bought	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-01-25	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-01-25	Premium	acquired	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-01-25	Premium	acquired	Premium	Premium	Premium	EVP of R&D
2024-01-25	Premium	acquired	Premium	Premium	Premium	Chief Technical Officer
2024-01-25	Premium	acquired	Premium	Premium	Premium	-
2024-01-25	Premium	acquired	Premium	Premium	Premium	SVP, General Counsel
2024-01-22	Premium	sold (taxes)	Premium	Premium	Premium	EVP of R&D
2023-12-18	Premium	sold	Premium	Premium	Premium	-
2023-10-16	Premium	acquired	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2023-08-14	Premium	acquired	Premium	Premium	Premium	GENERAL COUNSEL
2023-08-10	Premium	acquired	Premium	Premium	Premium	SVP, Finance
2023-08-07	Premium	sold	Premium	Premium	Premium	-
2023-06-13	Premium	acquired	Premium	Premium	Premium	-
2023-06-13	Premium	acquired	Premium	Premium	Premium	-
2023-06-13	Premium	acquired	Premium	Premium	Premium	-
2023-06-13	Premium	acquired	Premium	Premium	Premium	-
2023-04-24	Premium	acquired	Premium	Premium	Premium	Chief Technical Officer
2023-04-01	Premium	acquired	Premium	Premium	Premium	VP, Corporate Counsel
2023-03-22	Premium	acquired	Premium	Premium	Premium	EVP of R&D
2023-03-22	Premium	acquired	Premium	Premium	Premium	Chief Technical Officer
2023-03-22	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-03-22	Premium	acquired	Premium	Premium	Premium	-

ALLO - Allogene Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for ALLO